A stark transatlantic regulatory split leaves patients in one hemisphere stranded without critical therapies.
Differing regulatory risk tolerances and data interpretations between the FDA and European authorities create a geographical divide where patients are denied access to approved treatments.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
While U.S. patients can access narsoplimab following FDA approval, European patients are shut out after the EMA's CHMP rejected the exact same clinical data package.
The European approval of tolebrutinib contrasted with a stall by the FDA leaves US progressive MS patients without access to a novel disease-modifying therapy.
Differing administrative flexibilities between the FDA and EMA forced the complete withdrawal of the European application while the US review remains on track.
European regulators issued a negative opinion on a stem-cell transplant therapy that had already secured FDA approval in the United States.
The negative opinion from European regulators on narsoplimab halts its commercial path in Europe despite its existing approval in the United States.